ISHITA DRUGS & INDUSTRIES LTD.
Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.
Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad.
E-mail : ishitadrugs@gmail.com | info@ishitadrugs.com | **URL :** www.ishitadrugs.com
Phone : +91 7226995613/14/15 | +91 79 4002 3839

Date: 08.08.2026

To,
The Department of Corporate Services,
BSE Limited.
Floor No. 25, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.

Scrip Code: 524400

Dear Sir/Madam,

Subject: Outcome of Board Meeting held on 08th August, 2026

Pursuant to the regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of Ishita Drugs and Industries Limited, held its meeting today i.e. Saturday, 08th August, 2026.

1. The Board of Directors approved the Unaudited Financial Results of the Company for the quarter ended 30th June, 2026. The Limited Review Report issued by the Statutory Auditors of the Company is enclosed herewith.

2. Based on the recommendation of Nomination and Remuneration Committee, Board of Directors have approved the re-appointment of Mrs. Abha Agrawal (DIN 01589479) as a Non-Executive Non-Independent Director of the Company post attaining the age of 75 years, and, who retires by rotation, being eligible, offers herself for re-appointment, which is subject to the approval of the shareholders of the Company.

   On the basis of the disclosures received from Mrs. Abha Agrawal (DIN 01589479), it is hereby confirmed that she is not debarred from holding the office of Director by virtue of any order passed by the SEBI or any other such authority.

   The required details pursuant to SEBI Listing regulations are annexed herewith as **Annexure – I**.

   The composition of Board of Directors of the Company is in compliance with the requirements prescribed under the Companies Act, 2013 and SEBI Listing Regulations.

ISHITA

ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.
Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad.
E-mail : ishitadrugs@gmail.com | info@ishitadrugs.com | **URL :** www.ishitadrugs.com
Phone : +91 7226995613/14/15 | +91 79 4002 3839

3. The Board considered and approved the amendment in the Notice for convening the 33rd Annual General Meeting of the Company.

4. Based on evaluation by Audit Committee and recommendation of Nomination and remuneration committee, Board of Directors accepted the revised remuneration proposal of Mr. Sumit Agrawal, Chief Financial Officer of the Company.

5. Discussed the upgradation project of manufacturing facility for compliance with Revised Schedule M.

The Managing Director informed that the upgradation work is ongoing. The construction of a new block, envisaged to accommodate the new warehouse area, has been completed and civil work is going on for the extension of the existing buildings. Till date, the Company has spent nearly Rs. 435 lakh towards renovation of existing buildings and construction of new blocks. Further, capital contracts / orders of about Rs. 565 lakh have been issued for various utilities and equipments. The Company is also actively negotiating with different banks to raise funds for financing this upgradation project.

The meeting was commenced at 02:30 p.m. and concluded at 03:25 p.m.

Please take the above details on your records.

Thanking You.

For, Ishita Drugs and Industries Limited

Jagdishprasad Gokulchand Agrawal

Digitally signed by Jagdishprasad Gokulchand Agrawal
DN: c=IN, o=Personal,CID - 7001476, pseudonym=20241010172430721, 2.5.4.20=1cf1e826816b9b733fb573f3137ad7ca40c4070d181d5b9ad729120642b26ca1, postalCode=380007, st=Gujarat, title=5187, serialNumber=29a161557a206f00835c0ff46aae29f65f163262d574e5b8942b70273488da11, cn=Jagdishprasad Gokulchand Agrawal
Date: 2026.08.08 15:24:06 +05'30'

Jagdish Agrawal
Managing Director
DIN: 01031687

Jaymin Shah & Associates
Chartered Accountants

Office Address :
C-10 Soham Complex,
2nd Floor, Soni ni Chawl, Cross Road,
Odhav, Ahmedabad-382415

Date: 08/08/2026

To,
The Board of Directors,
Ishita Drugs & Industries Limited,
Ahmedabad.

LIMITED REVIEW REPORT

We have reviewed the accompanying of unaudited financial results of **ISHITA DRUGS AND INDUSTRIES LIMITED** for the period **01 Apr 2026 to 30 Jun 2026.** (The Statement) being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of **Interim financial information performed by the Independent auditor of the entity issued by the Institute of Chartered Accountants of India.** This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with Indian accounting standards prescribe under section 133 of companies Act,2013 read with relevant rules issued there under and another recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of
JAYMIN SHAH & ASSOCIATES
Chartered Accountants

Mayank Sancheti

JAYMIN SHAH & ASSOCIATES
AHMEDABAD
FRN : 129406W
CHARTERED ACCOUNTANTS

CA Mayank Sancheti
M No. :170863
Date: 08/08/2026
Place: Ahmedabad
UDIN: 26170863HUMIOX6931

Corp. Office : 410-411, Lilamani Corporate Heights, Opp. Ramapir Brts Bus Stand, Nr. Ozone Aangan, New Wadaj, Ahmedabad - 380013, Gujarat
Branch Office : 504, Palladium Business Hub, Above Pantaloons, Opp. 4D Mall - PVR Cinema, Visat-Gandhinagar Highway, Ahmedabad-382424

CA Mayank Sancheti +91 8000331632 / 7048685472
GSTIN : 24AAOFJ1119R1ZY
camayanksancheti@gmail.com

ISHITA DRUGS AND INDUSTRIES LIMITED
CIN: L24231GJ1992PLC017054
Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand
Ahmedabad – 382170
Website: www.ishitadrugs.com
Contact: +91 7226995613

Unaudited Financial Results for the Quarter Ended June 30, 2026

Amount in Lacs except Per Share data

	Particulars	Figures for 3 Months Ended	Figures for Preceding 3 Months Ended	Figures for Corresponding 3 Months in the previous Year Ended	Figures for the previous year Ended
		Un-audited	Audited	Un-audited	Audited
		30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
1	**INCOME**				
	Revenue from Operations	**314.53**	305.54	540.05	1466.02
	Other Income	**3.63**	21.86	9.11	47.32
	Total Income	**318.16**	**327.40**	**549.16**	**1513.34**
2	**EXPENSES**				
(a)	Cost of Material Consumed	**138.45**	257.68	379.59	1015.06
(b)	Purchase of Stock-In-Trade	**0.00**	(0.05)	23.92	41.73
(c)	Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	**34.09**	(29.76)	1.41	(25.54)
(d)	Employee Benefit Expense	**37.45**	35.24	33.60	137.93
(e)	Finance Cost	**0.47**	1.69	2.33	5.92
(f)	Depreciation, Depletion and Amortisation Expense	**4.98**	1.72	2.75	9.96
(g)	Other Expense	**72.70**	32.99	66.83	220.28
	Total Other Expenses	**72.70**	**32.99**	**66.83**	**220.28**
	Total Expenses	**288.14**	**299.51**	**510.43**	**1405.34**
3	**Total Profit before Exceptional Items and Tax**	**30.02**	**27.89**	**38.73**	**108.00**
4	Exceptional Items	0.00	0.00	0.00	0.00
5	**Total Profit before Tax**	**30.02**	**27.89**	**38.73**	**108.00**
6	Tax Expense				
7	Current Tax	**7.00**	10.08	8.50	30.08
8	Deferred Tax	**0.00**	0.07	0.00	0.07
9	Total Tax Expenses	**7.00**	**10.15**	**8.50**	**30.15**
10	Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00		0.00	0.00
11	**Net Profit Loss for the period from continuing operations**	**23.02**	**17.74**	**30.23**	**77.85**

ISHITA DRUGS & INDUSTRIES LTD. * AHMEDABAD *

Jaydeep agrawal

12	Profit / (Loss) from discontinued operations before tax	**0.00**	0.00	0.00	0.00
13	Tax Expenses of discontinued operations	**0.00**	0.00	0.00	0.00
14	Net Profit / (Loss) from discontinued operations after tax	**0.00**	0.00	0.00	0.00
15	Share of Profit / (Loss) of associates and joint ventures accounted for using equity method	**0.00**	0.00	0.00	0.00
16	**Total Profit / (Loss) for the period**	**23.02**	**17.74**	**30.23**	**77.85**
17	Other Comprehensive Income net of Taxes	**0.00**	0.00	0.00	0.00
18	**Total Comprehensive Income for the Period**	**23.02**	17.74	30.23	77.85
19	**Total profit or loss attributable to**				
	Profit or loss, attributable to owners of parents	**0.00**	0.00	0.00	0.00
	Total Profit or loss, attributable to non-controlling interests	**0.00**	0.00	0.00	0.00
20	**Total comprehensive income for the period attributable to**				
	Comprehensive Income for the period attributable to the owners of parents	0.00	0.00	0.00	0.00
	Total comprehensive income for the period attributable to the owners of parent non-controlling interests	0.00	0.00	0.00	0.00
21	**Details of Equity Share Capital**				
	Paid-Up Equity Share Capital	**299.03**	299.03	299.03	299.03
	Face Value of Equity Share Capital	**10.00**	10.00	10.00	10.00
22	**Details of Debt Securities**				
	Paid-Up Debt Capital	**0.00**	0.00	0.00	0.00
	Face Value of Debt Securities	**0.00**	0.00	0.00	0.00
23	Reserves Excluding Revaluation Reserves	**0.00**	0.00	0.00	0.00
24	Debenture Redemption Reserve	**0.00**	0.00	0.00	0.00
25	**Earnings Per Share**				
(i)	**Earnings Per Share for continuing operations**				
	Basic Earnings / (Loss) per share from continuing operations	**0.77**	**0.59**	**1.01**	**2.60**
	Diluted Earnings / (Loss) per share from continuing operations	**0.77**	0.59	1.01	2.60
(ii)	**Earnings Per Share for discontinued operations**				
	Basic Earnings / (Loss) per share from discontinued operations	**0.00**	0.00	0.00	0.00
	Diluted Earnings / (Loss) per share from discontinued operations	**0.00**	0.00	0.00	0.00
(iii)	Earnings per Equity Share				
	Basic Earnings / (Loss) per share from continuing and discontinued operations	**0.77**	0.59	1.01	2.60
	Diluted Earnings / (Loss) per share from continuing and discontinued operations	**0.77**	0.59	1.01	2.60
26	Debt Equity Ratio	**0.00**	0.00	0.00	0.00
27	Debt Service Coverage Ratio	**0.00**	0.00	0.00	0.00
28	Interest Service Coverage Ratio	**0.00**	0.00	0.00	0.00

ISMITA DRUGS & INDUSTRIES LTD. * AHMEDABAD *

Jaydhim agrawal

NOTES

1. The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on August 08, 2026.

2. The Limited Review of the results has been completed by the Statutory Auditors of the Company.

3. As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment viz. "Pharmaceutical Business".

4. The financial results for the quarter ended 30th June, 2026 are Ind AS compliant. The management has exercised necessary due diligence to ensure that the financial results give a true and fair view. This information has not been subjected to limited review or audit.

5. Previous quarter's amounts have been re-grouped/re-classified, wherever considered necessary to make them comparable with those of the current quarter.

6. Results are available at Company's website www.ishitadrugs.com and also at www.bseindia.com.

For, **ISHITA DRUGS AND INDUSTRIES LIMITED**

Jagdish Agrawal

ISHITA DRUGS & INDUSTRIES LTD. AHMEDABAD

JAGDISH AGRAWAL

Place	**Ahmedabad**		**MANAGING DIRECTOR**
Date	**08-Aug-26**		**DIN: 01031687**

ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.
Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad.
E-mail : ishitadrugs@gmail.com | info@ishitadrugs.com | **URL :** www.ishitadrugs.com
Phone : +91 7226995613/14/15 | +91 79 4002 3839

Annexure – I

Information as required under Regulation 30 - of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

Sr. No.	Particulars	Details
1.	Reasons for Change viz. appointment, ~~resignation~~, ~~removal~~, ~~otherwise~~;	Re-appointment of Mrs. Abha Agrawal (DIN: 01589479) as Non-Executive Non-Independent Director notwithstanding her attaining the age of 75 years.
2.	Date of appointment /~~cessation~~ (as applicable) & terms of appointment	Date of re- appointment shall be the date of approval of the shareholders.
3.	Brief Profile	Mrs. Abha Agrawal is a promoter of the Company and has been associated with the Company since inception. She has an extensive experience of business matters. She has been independently running successful business operations in the field of chemicals and electrical switches & circuit breakers for more than 30 years. She has vast exposure to business environment and contacts with senior leaders in the chemical industry.
4.	Disclosure of relationships between directors (in case of appointment of a director)	No relationship with any Directors except: Mr. Jagdish Agrawal, Managing Director (Spouse)
5.	Declaration as required under Circular No. LIST/COMP/14/2018-19 dated June 20, 2018	Mrs. Abha Agrawal is not debarred from holding office of a director by virtue of any SEBI order or any other such authority.